StreetInsider.com News Articles

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 17 Jun 2026 16:15:00 -0400

Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis

Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028

BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 17 Jun 2026 16:15:00 -0400

Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis

Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028

Wedbush Starts Odyssey Therapeutics (ODTX) at Outperform

Tue, 02 Jun 2026 06:59:50 -0400

Wedbush analyst David Nierengarten initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Outperform rating and a price target of $30.00.

For an analyst ratings summary and ratings history on Odyssey Therapeutics click here. For more ratings news on Odyssey Therapeutics click here.

Shares of Odyssey Therapeutics closed at $16.96 yesterday.

Oppenheimer Starts Odyssey Therapeutics (ODTX) at Outperform

Tue, 02 Jun 2026 06:07:51 -0400

(Updated - June 2, 2026 6:07 AM EDT)

Oppenheimer initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Outperform rating and a price target of $40.00.

The analyst comments "We are initiating coverage of ODTX with an Outperform rating and $40 PT following the completion of the company's initial public offering on May 8th. The company's lead candidate, OD-001, has demonstrated clinical proof-of-concept in ulcerative colitis (UC), and represents a differentiated asset in the ~$10B UC space, given its novel mechanism (targeting RIPK2) and oral profile, with additional potential upside in CD. ODTX's pipeline includes other promising candidates, targeting SLC15A4 and TNFR2,

Oppenheimer Starts Odyssey Therapeutics (ODTX) at Outperform

Tue, 02 Jun 2026 06:07:51 -0400

(Updated - June 2, 2026 6:07 AM EDT)

Oppenheimer initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Outperform rating and a price target of $40.00.

Cantor Fitzgerald Starts Odyssey Therapeutics (ODTX) at Overweight

Tue, 02 Jun 2026 06:04:43 -0400

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Overweight rating.

For an analyst ratings summary and ratings history on Odyssey Therapeutics click here. For more ratings news on Odyssey Therapeutics click here.

Shares of Odyssey Therapeutics closed at $16.96 yesterday.

TD Cowen Starts Odyssey Therapeutics (ODTX) at Buy

Tue, 02 Jun 2026 05:34:08 -0400

TD Cowen analyst Tyler Van Buren initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Buy rating.

The analyst comments "Odyssey is pursuing novel biology for large I&I markets with world-class management; we initiate at Buy. The lead oral RIPK2i for UC generated a 27% clinical remission rate, which held up at 25% in treatment-experienced patients & is a result of the upstream MoA. The SCL15A4 inhibitor for B-cell autoimmune disease & TNFR2 agonist for I&I are also intriguing, offering significant potential upside."

For an analyst ratings summary and ratings history on Odyssey Therapeutics click here. For more ratings news on

TD Cowen Starts Odyssey Therapeutics (ODTX) at Buy

Tue, 02 Jun 2026 05:34:08 -0400

TD Cowen analyst Tyler Van Buren initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Buy rating.

For an analyst ratings summary and ratings history on Odyssey Therapeutics click here. For more ratings news on

JPMorgan Starts Odyssey Therapeutics (ODTX) at Overweight

Tue, 02 Jun 2026 00:54:37 -0400

JPMorgan analyst Brian Cheng initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Overweight rating and a price target of $26.00.

The analyst comments: “ODTX is a clinical-stage biotech co. working on novel mechanistic approaches and unique targets for I&I indications. Spearheaded by an experienced team, ODTX is today at its core led by RIPK2 inhibitor (OD-001), which has demonstrated a clear case in the ulcerative colitis (UC) Ph 2a trial. Based on the Ph 2a data, we believe ‘001 is an active drug for IBD, notably with the ability to deliver a solid remission profile in pts who are harder

JPMorgan Starts Odyssey Therapeutics (ODTX) at Overweight

Tue, 02 Jun 2026 00:54:37 -0400

JPMorgan analyst Brian Cheng initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Overweight rating and a price target of $26.00.

Form 4 Odyssey Therapeutics, For: May 11 Filed by: TPG GP A, LLC

Wed, 13 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260513/26487451.html

Form 4 Odyssey Therapeutics, For: May 08 Filed by: Dimension Capital II, L.P.

Tue, 12 May 2026 17:38:00 -0400

si-local-file:///var/storage/secattach/20260512/26479586.html

Form 3 Odyssey Therapeutics, For: May 07 Filed by: Dimension Capital II, L.P.

Tue, 12 May 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260512/26479581.html

Form 4 Odyssey Therapeutics, For: May 11 Filed by: George Simeon

Mon, 11 May 2026 21:12:00 -0400

si-local-file:///var/storage/secattach/20260511/26471248.html

Form 4 Odyssey Therapeutics, For: May 07 Filed by: LEIDEN JEFFREY M

Mon, 11 May 2026 20:35:00 -0400

si-local-file:///var/storage/secattach/20260511/26471210.html

Form 4 Odyssey Therapeutics, For: May 08 Filed by: Haas Jason

Mon, 11 May 2026 20:33:00 -0400

si-local-file:///var/storage/secattach/20260511/26471207.html

Form 4 Odyssey Therapeutics, For: May 07 Filed by: Opipari Anthony W.